Millions of newborns worldwide are screened soon after birth to detect inherited disorders before symptoms appear. Traditional newborn screening (NBS) programs, which rely on biochemical markers, have been highly successful at identifying treatable conditions early. However, as research continues to uncover genetic diseases that emerge in infancy, experts are questioning whether current screening approaches can keep pace with genomic medicine.
Zhelan Huang from the Children’s Hospital of Fudan University and Wenhao Zhou from Guangzhou Women and Children’s Medical Center have reviewed the growing use of next‑generation sequencing (NGS) in modernizing NBS. Their paper, published in Pediatric Investigation, discusses the transition from biochemical testing for single diseases to genomic screening capable of detecting multiple conditions at once. It also outlines key challenges in incorporating genomic NBS (gNBS) into healthcare systems.
Dr. Zhou noted, “Conventional NBS methods are inherently constrained by their reliance on measurable biochemical abnormalities. While effective for disorders like phenylketonuria or congenital hypothyroidism, many genetic diseases do not produce detectable metabolic signals during the neonatal period. Consequently, affected infants appear healthy at birth but develop symptoms after irreversible damage has already occurred.”
By analyzing DNA directly, NGS provides a way to identify risks at the earliest stage of life.
In gNBS, NGS is applied to the same dried blood spots already collected for routine screening. Techniques like targeted gene panels, whole‑exome sequencing, and whole‑genome sequencing enable the simultaneous analysis of multiple genes linked to inherited diseases, expanding detection beyond the reach of biochemical assays.
Despite its promise, genomic screening also poses new challenges. Variants of uncertain significance make interpretation difficult and can cause unnecessary anxiety. Ethical considerations, including which genes to report and how to handle incidental or adult‑onset findings, require careful policy design. Turnaround time is another obstacle because sequencing results often take longer than conventional tests.
The review concludes that while cost, logistics, and ethics remain hurdles, advances in technology and supportive policies are expected to further integrate NGS with traditional screening programs. Used together, these methods could enhance early diagnosis, clarify uncertain results, and strengthen newborn health management from the start of life.
Publication details: Huang Z, Zhou W. Next-generation sequencing in newborn screening: Current status, challenges, and future perspectives. Pediatr Investig. 2026; 00: 1-16. https://doi.org/10.1002/ped4.70030
Zhelan Huang from the Children’s Hospital of Fudan University and Wenhao Zhou from Guangzhou Women and Children’s Medical Center have reviewed the growing use of next‑generation sequencing (NGS) in modernizing NBS. Their paper, published in Pediatric Investigation, discusses the transition from biochemical testing for single diseases to genomic screening capable of detecting multiple conditions at once. It also outlines key challenges in incorporating genomic NBS (gNBS) into healthcare systems.
Dr. Zhou noted, “Conventional NBS methods are inherently constrained by their reliance on measurable biochemical abnormalities. While effective for disorders like phenylketonuria or congenital hypothyroidism, many genetic diseases do not produce detectable metabolic signals during the neonatal period. Consequently, affected infants appear healthy at birth but develop symptoms after irreversible damage has already occurred.”
By analyzing DNA directly, NGS provides a way to identify risks at the earliest stage of life.
In gNBS, NGS is applied to the same dried blood spots already collected for routine screening. Techniques like targeted gene panels, whole‑exome sequencing, and whole‑genome sequencing enable the simultaneous analysis of multiple genes linked to inherited diseases, expanding detection beyond the reach of biochemical assays.
Despite its promise, genomic screening also poses new challenges. Variants of uncertain significance make interpretation difficult and can cause unnecessary anxiety. Ethical considerations, including which genes to report and how to handle incidental or adult‑onset findings, require careful policy design. Turnaround time is another obstacle because sequencing results often take longer than conventional tests.
The review concludes that while cost, logistics, and ethics remain hurdles, advances in technology and supportive policies are expected to further integrate NGS with traditional screening programs. Used together, these methods could enhance early diagnosis, clarify uncertain results, and strengthen newborn health management from the start of life.
Publication details: Huang Z, Zhou W. Next-generation sequencing in newborn screening: Current status, challenges, and future perspectives. Pediatr Investig. 2026; 00: 1-16. https://doi.org/10.1002/ped4.70030
Comment